Association between sensitivity to L-asparaginase in human cutaneous melanoma cells and asparagine synthetase and glutamine synthetase gene expression

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

BACKGROUND: L-asparaginase is an enzyme used in clinical practice for the treatment of some blood cancers. It has an antiproliferative effect in some solid tumors. To increase the efficacy of L-asparaginase, it is relevant to identify markers that predict tumor sensitivity to this enzyme. The expression of the ASNS and GLUL genes in tumor cells was previously proposed as such a marker. However, for some tumors, including melanoma, data on the association between the expression of these genes and sensitivity to L-asparaginase are absent or limited.

AIM: The work aimed to assess the association between sensitivity to L-asparaginase in melanoma cells and expression of the ASNS and GLUL genes.

METHODS: The cytotoxicity was assessed using the MTT assay in 35 cell lines. Gene expression was assessed using real-time reverse transcription polymerase chain reaction. The Spearman’s correlation coefficient was used to assess the association between expression and sensitivity.

RESULTS: The calculated IC50 for L-asparaginase in melanoma cell cultures was 0.01–199.91 IU/mL (median: 2.96 IU/mL; arithmetic mean: 16.95 IU/mL). The ASNS gene expression was 0.02–7.38 (median: 0.4; arithmetic mean: 0.98). The GLUL gene expression was 0.06–14.78 (median: 0.64; arithmetic mean: 1.41). The correlation between IC50 and ASNS expression was confirmed by the Spearman’s correlation coefficient of 0.751. There was no correlation between IC50 and GLUL expression (Spearman’s correlation coefficient: 0.077).

CONCLUSION: A positive correlation was confirmed between melanoma cell resistance to L-asparaginase and ASNS gene expression in these cells. A similar correlation for the GLUL gene was not confirmed.

About the authors

Ilya A. Kislyak

RUDN University; Blokhin National Medical Research Center of Oncology

Author for correspondence.
Email: kislyak.ilya.98@mail.ru
ORCID iD: 0000-0002-6042-9795
Russian Federation, Moscow; Moscow

Darina V. Sokolova

RUDN University; Blokhin National Medical Research Center of Oncology

Email: d.v.sokolova@gmail.com
ORCID iD: 0000-0003-3972-2425
SPIN-code: 2960-4800

Cand. Sci. (Biology)

Russian Federation, Moscow; Moscow

Olga S. Burova

Blokhin National Medical Research Center of Oncology

Email: burova-55@mail.ru
ORCID iD: 0000-0001-8897-0172
SPIN-code: 7748-4593

Cand. Sci. (Biology)

Russian Federation, Moscow

Irina I. Khan

RUDN University; Blokhin National Medical Research Center of Oncology

Email: irinchek05@gmail.com
ORCID iD: 0000-0003-2948-0872
SPIN-code: 6826-7694

Cand. Sci. (Biology)

Russian Federation, Moscow; Moscow

Dmitry D. Zhdanov

RUDN University; Orechovich Institute of Biomedical Chemistry

Email: zdanov_dd@pfur.ru
ORCID iD: 0000-0003-4753-7588
SPIN-code: 3845-2544

Dr. Sci. (Biology), Professor

Russian Federation, Moscow; Moscow

Vadim S. Pokrovsky

RUDN University; Blokhin National Medical Research Center of Oncology

Email: v.pokrovsky@ronc.ru
ORCID iD: 0000-0003-4006-9320
SPIN-code: 4552-1226

MD, Dr. Sci. (Medicine), Professor

Russian Federation, Moscow; Moscow

References

  1. Bender C, Maese L, Carter-Febres M, Verma A. Clinical Utility of Pegaspargase in Children, Adolescents and Young Adult Patients with Acute Lymphoblastic Leukemia: A Review. Blood Lymphat Cancer. 2021;11:25–40. doi: 10.2147/BLCTT.S245210
  2. Juluri KR, Siu C, Cassaday RD. Asparaginase in the Treatment of Acute Lymphoblastic Leukemia in Adults: Current Evidence and Place in Therapy. Blood Lymphat Cancer. 2022;12:55–79. doi: 10.2147/BLCTT.S342052
  3. Pokrovsky VS, Vinnikov D. L-Asparaginase for newly diagnosed extra-nodal NK/T-cell lymphoma: systematic review and meta-analysis. Expert Rev Anticancer Ther. 2017;17(8):759–768. doi: 10.1080/14737140.2017.1344100
  4. Wang N, Ji W, Wang L, et al. Overview of the structure, side effects, and activity assays of l-asparaginase as a therapy drug of acute lymphoblastic leukemia. RSC Med Chem. 2022;13(2):117–128. doi: 10.1039/d1md00344e
  5. Hammel P, Fabienne P, Mineur L, et al. Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial. Eur J Cancer. 2020;124:91–101. doi: 10.1016/j.ejca.2019.10.020
  6. Hortobagyi GN, Yap HY, Wiseman CL, et al. Chemoimmunotherapy for metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, methotrexate, L-asparaginase, Corynebacterium parvum, and Pseudomonas vaccine. Cancer Treat Rep. 1980;64(1):157–9.
  7. Rudnick SA, Neijstrom E, Capizzi RL, et al. Randomized phase II comparison of methotrexate with or without L-asparaginase in non-small cell cancer of the lung. Cancer Treat Rep. 1982;66(3):541–4.
  8. Zhdanov DD, Pokrovsky VS, Pokrovskaya MV, et al. Rhodospirillum rubruml-asparaginase targets tumor growth by a dual mechanism involving telomerase inhibition. Biochem Biophys Res Commun. 2017;492(2):282–288. doi: 10.1016/j.bbrc.2017.08.078
  9. Kislyak IA, Pokrovskaya MV, Zhanturina DYu, Pokrovsky VS. The use of L-asparaginase for the treatment of solid tumors: data from experimental studies and clinical trials. Russian Journal of Oncology. 2023;28(1):79–94. doi: 10.17816/onco562802 EDN: TCOHLO
  10. Kislyak IA, Pokrovsky VS. Biochemical markers of tumor cell sensitivity to L-asparaginase. Biochemistry (Moscow), Supplement Series B: Biomedical Chemistry. 2023;17(3):111–125. doi: 10.1134/S1990750823600541
  11. Lorenzi PL, Reinhold WC, Rudelius M, et al. Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells. Mol Cancer Ther. 2006;5(11):2613–23. doi: 10.1158/1535-7163.MCT-06-0447
  12. Panosyan EH, Wang Y, Xia P, et al. Asparagine depletion potentiates the cytotoxic effect of chemotherapy against brain tumors. Mol Cancer Res. 2014;12(5):694–702. doi: 10.1158/1541-7786.MCR-13-0576
  13. Scherf U, Ross DT, Waltham M, et al. A gene expression database for the molecular pharmacology of cancer. Nat Genet. 2000;24(3):236–44. doi: 10.1038/73439
  14. Zhang B, Dong LW, Tan YX, et al. Asparagine synthetase is an independent predictor of surgical survival and a potential therapeutic target in hepatocellular carcinoma. Br J Cancer. 2013;109(1):14–23. doi: 10.1038/bjc.2013.293
  15. Blachier J, Cleret A, Guerin N, et al. L-asparaginase anti-tumor activity in pancreatic cancer is dependent on its glutaminase activity and resistance is mediated by glutamine synthetase. Exp Cell Res. 2023;426(2):113568. doi: 10.1016/j.yexcr.2023.113568
  16. Rotoli BM, Uggeri J, Dall’Asta V, et al. Inhibition of glutamine synthetase triggers apoptosis in asparaginase-resistant cells. Cell Physiol Biochem. 2005;15(6):281–92. doi: 10.1159/000087238
  17. Schmidt A, Armento A, Bussolati O, et al. Hepatoblastoma: glutamine depletion hinders cell viability in the embryonal subtype but high GLUL expression is associated with better overall survival. J Cancer Res Clin Oncol. 2021;147(11):3169–3181. doi: 10.1007/s00432-021-03713-4
  18. Tardito S, Chiu M, Uggeri J, et al. L-Asparaginase and inhibitors of glutamine synthetase disclose glutamine addiction of beta-catenin-mutated human hepatocellular carcinoma cells. Curr Cancer Drug Targets. 2011;11(8):929–43. doi: 10.2174/156800911797264725
  19. Apfel V, Begue D, Cordo V, et al. Therapeutic Assessment of Targeting ASNS Combined with l-Asparaginase Treatment in Solid Tumors and Investigation of Resistance Mechanisms. ACS Pharmacol Transl Sci. 2021;4(1):327–337. doi: 10.1021/acsptsci.0c00196
  20. Shishparenok AN, Koroleva SA, Dobryakova NV, et al. Bacterial cellulose films for L-asparaginase delivery to melanoma cells. Int J Biol Macromol. 2024;276(Pt 1):133932. doi: 10.1016/j.ijbiomac.2024.133932
  21. Shishparenok AN, Petryaev ER, Koroleva SA, et al. Bacterial Cellulose-Chitosan Composite for Prolonged-Action L-Asparaginase in Treatment of Melanoma Cells. Biochemistry (Moscow). 2024;89(10):1727–1743. doi: 10.1134/S0006297924100067
  22. Aslanian AM, Fletcher BS, Kilberg MS. Asparagine synthetase expression alone is sufficient to induce l-asparaginase resistance in MOLT-4 human leukaemia cells. Biochem J. 2001;357(Pt 1):321–8. doi: 10.1042/0264-6021:3570321
  23. Hermanova I, Zaliova M, Trka J, Starkova J. Low expression of asparagine synthetase in lymphoid blasts precludes its role in sensitivity to L-asparaginase. Exp Hematol. 2012;40(8):657–65. doi: 10.1016/j.exphem.2012.04.005
  24. Hutson RG, Kitoh T, Moraga Amador DA, et al. Amino acid control of asparagine synthetase: relation to asparaginase resistance in human leukemia cells. Am J Physiol. 1997;272(5 Pt 1):C1691-9. doi: 10.1152/ajpcell.1997.272.5.C1691
  25. Kiriyama Y, Kubota M, Takimoto T, et al. Biochemical characterization of U937 cells resistant to L-asparaginase: the role of asparagine synthetase. Leukemia. 1989;3(4):294–7.
  26. Dufour E, Gay F, Aguera K, et al. Pancreatic tumor sensitivity to plasma L-asparagine starvation. Pancreas. 2012;41(6):940–8. doi: 10.1097/MPA.0b013e318247d903
  27. Lorenzi PL, Llamas J, Gunsior M, et al. Asparagine synthetase is a predictive biomarker of L-asparaginase activity in ovarian cancer cell lines. Mol Cancer Ther. 2008;7(10):3123–8. doi: 10.1158/1535-7163.MCT-08-0589
  28. Kim GW, Lee DH, Jeon YH, et al. Glutamine Synthetase as a Therapeutic Target for Cancer Treatment. Int J Mol Sci. 2021;22(4):1701. doi: 10.3390/ijms22041701

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2025 Eco-Vector

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
 


Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).